S&P 500   3,081.11 (-0.35%)
DOW   27,600.66 (-0.33%)
QQQ   200.77 (-0.39%)
BABA   186.97 (+0.00%)
F   8.96 (-0.88%)
ACB   3.56 (-0.28%)
DIS   138.58 (+0.00%)
S&P 500   3,081.11 (-0.35%)
DOW   27,600.66 (-0.33%)
QQQ   200.77 (-0.39%)
BABA   186.97 (+0.00%)
F   8.96 (-0.88%)
ACB   3.56 (-0.28%)
DIS   138.58 (+0.00%)
Log in

TransEnterix Stock Price, Forecast & Analysis (NYSEAMERICAN:TRXC)

$0.31
+0.04 (+14.81 %)
(As of 11/13/2019 09:29 AM ET)
Today's Range
$0.27
Now: $0.31
$0.34
50-Day Range N/A
52-Week Range
$0.20
Now: $0.31
$3.62
Volume9.40 million shs
Average Volume2.77 million shs
Market Capitalization$79.25 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
TransEnterix, Inc, a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery. The company offers Senhance System, a multi-port robotic surgery system, which allows up to four arms to control robotic instruments and a camera in Europe. It also develops SurgiBot System, a single-port system robotically enhanced laparoscopic surgical platform.. Read More…

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Medical Instruments & Supplies
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:TRXC
CUSIPN/A
Phone+1-919-7658400

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Market Cap$79.25 million
Next Earnings DateN/A
OptionableOptionable

Receive TRXC News and Ratings via Email

Sign-up to receive the latest news and ratings for TRXC and its competitors with MarketBeat's FREE daily newsletter.


TransEnterix (NYSEAMERICAN:TRXC) Frequently Asked Questions

What is TransEnterix's stock symbol?

TransEnterix trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "TRXC."

How were TransEnterix's earnings last quarter?

TransEnterix, Inc. (NYSEAMERICAN:TRXC) released its quarterly earnings results on Wednesday, August, 7th. The medical instruments supplier reported ($0.09) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.08) by $0.01. The medical instruments supplier had revenue of $3.64 million for the quarter, compared to analyst estimates of $5.13 million. View TransEnterix's Earnings History.

What price target have analysts set for TRXC?

3 brokerages have issued 12-month price targets for TransEnterix's shares. Their forecasts range from $1.00 to $3.00. On average, they anticipate TransEnterix's share price to reach $1.87 in the next twelve months. This suggests a possible upside of 502.2% from the stock's current price. View Analyst Price Targets for TransEnterix.

What is the consensus analysts' recommendation for TransEnterix?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TransEnterix in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for TransEnterix.

Has TransEnterix been receiving favorable news coverage?

Media stories about TRXC stock have trended very negative this week, InfoTrie Sentiment reports. The research firm scores the sentiment of press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. TransEnterix earned a coverage optimism score of -3.2 on InfoTrie's scale. They also gave headlines about the medical instruments supplier a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the near future. View News Stories for TransEnterix.

Are investors shorting TransEnterix?

TransEnterix saw a increase in short interest in October. As of October 15th, there was short interest totalling 19,380,000 shares, an increase of 6.4% from the September 15th total of 18,210,000 shares. Based on an average daily volume of 2,950,000 shares, the short-interest ratio is currently 6.6 days. Approximately 9.3% of the shares of the company are short sold. View TransEnterix's Current Options Chain.

Who are some of TransEnterix's key competitors?

What other stocks do shareholders of TransEnterix own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TransEnterix investors own include Oramed Pharmaceuticals (ORMP), Compugen (CGEN), Editas Medicine (EDIT), Ekso Bionics (EKSO), XOMA (XOMA), NVIDIA (NVDA), Actinium Pharmaceuticals (ATNM), Geron (GERN), Opko Health (OPK) and Advanced Micro Devices (AMD).

Who are TransEnterix's key executives?

TransEnterix's management team includes the folowing people:
  • Mr. Todd M. Pope, CEO, Pres & Director (Age 53)
  • Mr. Joseph P. Slattery, Exec. VP, CFO & Principal Accounting Officer (Age 53)
  • Mr. Anthony Fernando, COO, CTO & Exec. VP (Age 46)
  • Mr. Joshua B. Weingard, Chief Legal Officer & Sec. (Age 45)
  • Dr. Stephanie M. Fitts Ph.D., VP of RA/QA, Clinical and Compliance (Age 52)

Who are TransEnterix's major shareholders?

TransEnterix's stock is owned by a number of of retail and institutional investors. Top institutional investors include First Trust Advisors LP (0.61%), Prospera Financial Services Inc (0.10%) and Tradewinds Capital Management LLC (0.04%). Company insiders that own TransEnterix stock include Anthony C J Fernando, Joseph P Slattery, Todd Pope and William N Starling Jr. View Institutional Ownership Trends for TransEnterix.

Which major investors are buying TransEnterix stock?

TRXC stock was bought by a variety of institutional investors in the last quarter, including First Trust Advisors LP, Prospera Financial Services Inc and Tradewinds Capital Management LLC. View Insider Buying and Selling for TransEnterix.

How do I buy shares of TransEnterix?

Shares of TRXC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is TransEnterix's stock price today?

One share of TRXC stock can currently be purchased for approximately $0.31.

How big of a company is TransEnterix?

TransEnterix has a market capitalization of $79.25 million. View Additional Information About TransEnterix.

What is TransEnterix's official website?

The official website for TransEnterix is http://www.transenterix.com/.

How can I contact TransEnterix?

TransEnterix's mailing address is 635 Davis Dr Ste 300, MORRISVILLE, NC 27560-7199, United States. The medical instruments supplier can be reached via phone at +1-919-7658400.


MarketBeat Community Rating for TransEnterix (NYSEAMERICAN TRXC)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  368 (Vote Outperform)
Underperform Votes:  424 (Vote Underperform)
Total Votes:  792
MarketBeat's community ratings are surveys of what our community members think about TransEnterix and other stocks. Vote "Outperform" if you believe TRXC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TRXC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/13/2019 by MarketBeat.com Staff

Featured Article: What is a Special Dividend?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel